JP2021161105A - Composition for preventing or treating chronic or acute virus infection and/or sepsis in humans or animals - Google Patents

Abstract

To provide: a composition or medicine for treating COVID-19; and a medicine for treating chronic or acute virus infection and/or sepsis mainly in humans, the medicine indicating a superior antiviral effect to the antiviral effect of conventionally known I2 and DMSO.SOLUTION: A composition for preventing or treating chronic or acute virus infection and/or sepsis in humans or animals contains at least one iodine source selected from the group consisting of iodide salts and povidone-iodine, and at least one sulfur source selected from the group consisting of dimethyl sulfoxide and methylsulfonylmethane.SELECTED DRAWING: None

Description

The present invention relates to compositions for the prevention or treatment of chronic or acute viral infections and / or sepsis in humans or animals.

Mortality from viral infections such as SARS (Severe Acute Respiratory Syndrome), norovirus, and bird flu has increased in recent history. Since December 8, 2019, several cases of unexplained pneumonia have been reported in Wuhan, Hubei Province, China (Lu h 2020). This recent epidemic of coronavirus, later named COVID-19, poses a global threat due to its high infectivity and pathogenicity.

The emergence of a new influenza virus is an urgent issue that requires immediate attention. The development of antiviral vaccines is a solution to these problems, but vaccines are only effective in preventing the transmission of certain viruses. Vaccine research, development, and production also require considerable time and financial resources and is at high risk of failure. Given how fast new coronaviruses, including those that cause COVID-19, are spreading, they are effective against a wide range of viruses while enhancing innate and adaptive antiviral protection as prophylactic and therapeutic agents. Antiviral agents are in urgent need.

Viral respiratory tract infections are an important cause of morbidity and mortality worldwide. Fisher et al. Show that the LPO / I ₂ / H ₂ O ₂ oxidative host defense system has potent activity against two major respiratory viral pathogens, adenovirus and RSV. In addition, the lactoperoxidase / I ₂ / H ₂ O ₂ system may contribute to airway antiviral protection and enhance innate antiviral immunity by delivering ^{I −} to the airway mucosa (Non-Patent Document 1). ). This study can contribute to airway antiviral defense by activating _{the lactoperoxidase / I 2} / H ₂ O ₂ system with iodide compounds, and the innate antivirus by delivering ^{I − to the airway mucosa.} It suggests that it may enhance immunity.

Zinc (Zn) is an important trace element and plays an important role in initiating and maintaining a strong immune response. In addition, Zn is a hitrinovirus (Korant and Butterworth, 1976 , Geist et al., 1987 ), a simple herpesvirus ( Kuemel et al., 1990 , Arens and Travis, 2000 ), and a human immunodeficiency virus ( Haraguchi et al.). , 1999 ), Hepatitis C virus ( Yusa et al., 2006 ), Respiratory syncytial virus [RS virus] ( Suara and Crowe, 2004 ), Waxinia virus ( Katz and Margalith, 1981 ), Picorna virus (Krenn, Direct inhibitory effect against various viruses including B et al. 2009), coronavirus and arterivirus (Te Velthuiis AJ et al. 2010), and porcine coronavirus (Wei, Z, M et al. 2012). ..

Dimethyl sulfoxide (DMSO) is an all-natural substance derived from wood pulp. In 1963, it was discovered that the compound could penetrate without damaging the skin or other membranes and could carry the component into the biological system. DMSO can easily induce oxidative stress, increase oxygen levels and act as an antiviral agent. This compound has been shown to correct septic conditions associated with dysregulation of the immunoinflammatory response induced by viral infection (Non-Patent Document). Mechanically, DMSO is a potent antioxidant that can regulate the activation of transcription factors in septic animals and act as a carrier for other drugs.
There is a long history of safe use of DMSO in clinical practice.

Fischer, AJ, NJ Lennemann, S. Krishnamurthy, P. Pocza, L. Durairaj, JL Launspach, BA Rhein, C. Wohlford-Lenane, D. Lorentzen and B. Banfi (2011). "Enhancement of respiratory mucosal antiviral defenses by the oxidation of iodide. "American journal of respiratory cell and molecular biology 45 (4): 874-881. Houston, DM, JJ Bugert, SP Denyer and CM Heard (2017). "Potentiated virucidal activity of pomegranate rind extract (PRE) and punicalagin against Herpes simplex virus (HSV) when co-administered with zinc (II) ions, and antiviral activity of PRE against HSV and aciclovir-resistant HSV. "PloS one 12 (6). Huang, S.-H., C.-H. Wu, S.-J. Chen, H.-K. Sytwu and G.-J. Lin (2020). "Immunomodulatory effects and potential clinical applications of dimethyl sulfoxide. "Immunobiology: 151906. Iwata, A., M. L. Morrison and M. B. Roth (2014). "Iodide protects heart tissue from reperfusion injury." PloS one 9 (11). Krenn, B., E. Gaudernak, B. Holzer, K. Lanke, F. Van Kuppeveld and J. Seipelt (2009). "Antiviral activity of the zinc ionophores pyrithione and hinokitiol against picornavirus infections." Journal of virology 83 (1) ): 58-64. Read, S. A., S. Obeid, C. Ahlenstiel and G. Ahlenstiel (2019). "The role of zinc in antiviral immunity." Advances in Nutrition 10 (4): 696-710. Te Velthuis, AJ, SH van den Worm, AC Sims, RS Baric, EJ Snijder and MJ van Hemert (2010). "Zn2 + inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. "PLoS pathogens 6 (11). Wei, Z., M. Burwinkel, C. Palissa, E. Ephraim and M. F. Schmidt (2012). "Antiviral activity of zinc salts against transmissible gastroenteritis virus in vitro." Veterinary microbiology 160 (3-4): 468-472. Chang, CK, MV Albarillo and W. Schumer (2001). "Therapeutic effect of dimethyl sulfoxide on ICAM-1 gene expression and activation of NF-κB and AP-1 in septic rats." Journal of Surgical Research 95 (2): 181-187. Chang, CK, S. Llanes and W. Schumer (1999). "Inhibitory effect of dimethyl sulfoxide on nuclear factor-κB activation and intercellular adhesion molecule 1 gene expression in septic rats." Journal of Surgical Research 82 (2): 294- 299. Guo, Q., Q. Wu, D. Bai, Y. Liu, L. Chen, S. Jin, Y. Wu and K. Duan (2016). "Potential use of dimethyl sulfoxide in treatment of infections caused by Pseudomonas aeruginosa . "Antimicrobial agents and chemotherapy 60 (12): 7159-7169." Macdonald, J., H. F. Galley and N. R. Webster (2003). "Oxidative stress and gene expression in sepsis." British journal of anaesthesia 90 (2): 221-232. Han, B. and B. X. Hoang (2018). Metal complexes as pharmaceuticals for treatment and prevention of cancer and inflammatory diseases, Google Patents. Hoang, BX, B. Han, HX Nguyen and KT Dang (2018). "Nutritional Supplement" Bao Khi Khang "as an Adjuvant Therapy in Acute Exacerbations of Chronic Obstructive Pulmonary Disease." Journal of medicinal food 21 (10): 1053- 1059. Hoang, BX, B. Han, DG Shaw and M. Nimni (2016). "Zinc as a possible preventive and therapeutic agent in pancreatic, prostate, and breast cancer." European Journal of Cancer Prevention 25 (5): 457-461 .. Hoang, BX, BT Le, HD Tran, C. Hoang, HQ Tran, DM Tran, CQ Pham, TD Pham, TV Ha and NT Bui (2011). "Dimethyl sulfoxide-sodium bicarbonate infusion for palliative care and pain relief in patients with metastatic prostate cancer. "Journal of pain & palliative care pharmacotherapy 25 (4): 350-355. Hoang, B. X., S. A. Levine, D. G. Shaw, P. Pham and C. Hoang (2006). "Bronchial epilepsy or broncho-pulmonary hyper-excitability as a model of asthma pathogenesis." Medical hypotheses 67 (5): 1042-1051. Hoang, BX, DG Shaw, S. Levine, C. Hoang and P. Pham (2007). "New approach in asthma treatment using excitatory modulator." Phytotherapy Research: An International Journal Devoted to Pharmacological and Toxicological Evaluation of Natural Product Derivatives 21 (6): 554-557. Hoang, BX, G. Shaw, P. Pham and SA Levine (2010). "Lactobacillus rhamnosus cell lysate in the management of resistant childhood atopic eczema." Inflammation & Allergy-Drug Targets (Formerly Current Drug Targets-Inflammation & Allergy) 9 (3): 192-196. Hoang, BX, DM Tran, HQ Tran, PT Nguyen, TD Pham, HV Dang, TV Ha, HD Tran, C. Hoang and KN Luong (2011). "Dimethyl sulfoxide and sodium bicarbonate in the treatment of refractory cancer pain." Journal of pain & palliative care pharmacotherapy 25 (1): 19-24. X Hoang, B., S. A Levine, D. G Shaw, D. M Tran, H. Q Tran, P. MT Nguyen, H. D Tran, C. Hoang and P. T Pham (2010). "Dimethyl sulfoxide as an excitatory modulator and its possible role in cancer pain management. "Inflammation & Allergy-Drug Targets (Formerly Current Drug Targets-Inflammation & Allergy) 9 (4): 306-312. X Hoang, B., D. Graeme Shaw, P. Pham and S. A Levine (2010). "Treating asthma as a neuroelectrical disorder." Inflammation & Allergy-Drug Targets (Formerly Current Drug Targets-Inflammation & Allergy) 9 ( 2): 130-134.

The present invention relates to a composition comprising an iodine source and a sulfur source for treating and preventing chronic and acute viral infections and sepsis in humans and animals, in particular in the pharmaceutical field, eg, as a therapeutic agent for these symptoms. With respect to iodine and dimethylsulfoxide compositions.

Specifically, the present invention exhibits a composition or drug for the treatment of COVID-19, as well as a predominantly human chronic antiviral effect that is superior to _{the conventionally known antiviral effects of I 2 and DMSO.} Alternatively, the purpose is to provide a drug for treating acute viral infection and / or septicemia.

The present inventors have found that chronic or acute viral infection and / or sepsis in humans or animals can be treated by using a specific iodine source in combination with a specific sulfur source, and complete the present invention. I arrived.

That is, the present invention is as follows.
[1] A substance that produces iodine ions by dissolution in water and / or after administration, at least one iodine source selected from the group consisting of povidone iodine, and at least selected from the group consisting of dimethyl sulfoxide and methylsulfonylmethane. A composition for the prevention or treatment of chronic or acute viral infections and / or septicemia in humans or animals, comprising one source of iodine.
[2] Chronic human or animal, including at least one iodine source selected from the group consisting of iodide salts and povidone iodine, and at least one sulfur source selected from the group consisting of dimethyl sulfoxide and methylsulfonylmethane. Or a composition for the prevention or treatment of acute viral infection and / or sepsis.
[3] The composition according to [1] or [2], wherein the sulfur source is combined with the iodine source to enhance the therapeutic effect of the sulfur source.
[4] The daily dose of the iodine source and the sulfur source per 1 kg of human or animal body weight is 20 mol or more of sulfur atoms contained in the sulfur source per mol of iodine atoms contained in the iodine source. The composition according to any one of [1] to [3], which has a ratio of 200 mol or less.
[5] The dose of the iodine source per day of human or animal body weight is 1 part by mass with respect to 1 part by mass of the daily dose of the iodine source of human or animal.
When the iodine source is an iodide salt, it is 5 parts by mass or more and 100 parts by mass or less.
The composition according to any one of [1] to [4], wherein the iodine source is povidone iodine, which is 5 parts by mass or more and 100 parts by mass or less.
[6] The daily dose of the iodine source per kg of human or animal body weight is
When the iodine source is an iodide salt, it is 0.5 mg to 10 mg.
When the iodine source is povidone iodine, it is 0.5 mg to 50 mg.
The composition according to any one of [1] to [4], wherein the daily dose of the sulfur source per 1 kg of human or animal body weight is 10 to 1000 mg.
[7] The daily dose of the iodine source per kg of human or animal body weight is
When the iodine source is an iodide salt, it is 1 mg to 5 mg.
When the iodine source is povidone iodine, it is 1 mg to 40 mg.
The composition according to any one of [1] to [5], wherein the daily dose of the sulfur source per 1 kg of human or animal body weight is 100 to 500 mg.
[8] The iodine source is an iodide salt, the iodide salt is _{a metal salt other than zinc iodide (ZnI 2} ), and the metal salt is used together with a zinc salt other than zinc iodide.
The item according to any one of [1] to [7], wherein the iodide salt, which is a metal salt other than zinc iodide, is 2 to 20 parts by mass with respect to 1 part by mass of the zinc salt other than zinc iodide. Composition.
[9] The iodine source is an iodide salt, the iodide salt is _{a metal salt other than zinc iodide (ZnI 2} ), and the metal salt is used together with a zinc salt other than zinc iodide.
The item according to any one of [1] to [7], wherein the iodide salt, which is a metal salt other than zinc iodide, is 3 to 10 parts by mass with respect to 1 part by mass of the zinc salt other than zinc iodide. Composition.
[10] The iodine source is an iodide salt.
The composition according to any one of [1] to [7], wherein the iodide salt is _{at least one selected from the group consisting of ZnI 2} , CuI ₂ , FeI _{2, NaI and KI.}
[11] The iodine source is an iodide salt.
The composition according to any one of [1] to [7], wherein the iodide salt is _{a metal salt other than zinc iodide (ZnI 2) and is used together with a zinc salt other than zinc iodide.}
[12] The iodide salt is at least one selected from the group consisting _{of CuI 2} , FeI _{2 , NaI and KI, and is used together with zinc acetate ((CH 3} COO) ₂ Zn), according to [11]. Composition.
[13] At least one pharmaceutically acceptable dosage form selected from the group consisting of oral, parenteral, rectal, nasal spray, oral spray, transdermal, infusion, and aerosol spray, [1]-[ 12] The composition according to any one of the items.
[14] The composition according to any one of [1] to [13] for the prevention or treatment of COVID-19.
[15] An agent comprising at least one iodine source selected from the group consisting of an iodide salt and povidone iodine, and constituting the composition according to any one of claims 1 to 14.
[16] An agent comprising at least one sulfur source selected from the group consisting of dimethyl sulfoxide and methylsulfonylmethane, and constituting the composition according to any one of [1] to [14].
[17] A method for preventing or treating chronic or acute viral infection and / or sepsis, which comprises administering the composition according to any one of [1] to [14] to humans or animals.

According to the present invention, compositions or pharmaceuticals for the treatment of COVID-19, as well as predominantly human chronic or acute, exhibiting antiviral effects superior to those of _{conventionally known I 2 and DMSO.} Pharmaceuticals for treating viral infections and / or septicemia can be provided.

Specifically, the therapeutic combination of the present invention has a wide range of virucidal effects on DNA and RNA-containing viruses. In addition to the virus-killing effect, the therapeutic compositions of the present invention also exhibit anti-inflammatory, immunomodulatory and antioxidant effects. The compositions of the present invention can be used as effective and safe sterile and disinfectants for humans and animals.

Hereinafter, embodiments of the present invention will be described in detail, but the present invention is not limited to the following embodiments, and can be carried out with appropriate modifications within the scope of the object of the present invention. ..

<Composition for prevention or treatment of viral infection and / or sepsis>
A first aspect of the present invention is a composition for the prevention or treatment of viral infection and / or sepsis. The composition may be a composition for the prevention or treatment of chronic or acute viral infections and / or septicemia in humans or animals, preferably for chronic or acute viral infections and / or septicemia in humans. It is a composition for prevention or treatment, and more preferably a composition for treatment of chronic or acute viral infection and / or septicemia in humans.

The first aspect of the present invention is characterized in that a specific iodine source and a specific sulfur source are used in combination.
The particular iodine source is at least one selected from the group consisting of substances that produce iodine ions upon dissolution in water and / or after administration, and povidone iodine.

The substance that produces iodine ions by dissolution in water may be any substance that can generate iodine ions when mixed with a medium containing water. Here, the "medium containing water" may be only water, not only water, or a medium containing components other than water, and is typically a liquid dosage form. For example, liquids, injections, infusions, aerosols, gels, nasal sprays, oral sprays, sprays, etc., and powders (powder), granules, tablets, capsules, pills, etc. at the time of sale or provision. It may be a solid form of the dosage form to be mixed with a medium containing water at the time of administration.

Examples of substances that generate iodine ions after administration include substances that can generate iodine ions after administration to humans or animals. Specifically, specifically, after administration to a living body, body fluids (blood, lymph, digestion) in the living body (blood, lymph, digestion). Liquids, tissue fluids, liquids existing in cells, tissues, organs, etc., water existing in the living body, etc.) and waters derived from foods and drinks in the living body, which can generate iodine ions, and the like can be mentioned.

The specific iodine source may be a substance that produces iodine ions by dissolution in water, and may be a substance that produces iodine ions after administration.
A substance that produces iodine ions by dissolution in water and / or after administration is typically an iodide salt, and examples of the iodide salt include those described below. Povidone iodine may also be a substance that produces iodine ions upon dissolution in water and / or after administration.

The particular iodine source may also be at least one selected from the group consisting of iodide salts and povidone iodine. Here, the iodide salt and povidone iodine do not have to be substances that generate iodine ions by dissolution in water and / or after administration, but substances that generate iodine ions by dissolution in water and / or after administration. May be preferred.

Examples of the iodide salt include a metal salt of iodine, preferably at least one selected from the group consisting of _{ZnI 2} , CuI ₂ , FeI _{2 , NaI and KI, and preferably consisting of ZnI 2} , NaI and KI. It is more preferably at least one selected from the group, and _{even more preferably at least one selected from the group consisting of ZnI 2 and NaI.}

In the first aspect of the present invention, it is preferable to combine a specific iodine source, a specific sulfur source, and further a zinc source.
The zinc source is a substance that supplies zinc elements (including zinc atoms and zinc ions). Zinc sources include substances that produce zinc ions upon dissolution in water and / or after administration. Here, the substance that produces zinc ions by dissolution in water and / or after administration is referred to as "iodine ion" in the above description of "a substance that produces iodine ions by dissolution in water and / or after administration". It can be applied by replacing it with "zinc ion".

Zinc sources and / or substances that produce zinc ions upon dissolution in water and / or after administration typically include zinc salts, which contain anions or anions that have little or no potential for adverse effects on the body. Salts of substances (elements, atoms, compounds) that can be produced and zinc are preferable, and salts _{of carboxylic acids such as zinc iodide (ZnI 2} ) and acetic acid and zinc are more preferable, and zinc iodide and zinc acetate ((CH)). ₃ COO) ₂ Zn) is more preferable.
Since zinc iodide is the above-mentioned specific iodine source and also a zinc source, it can serve as both of them. Therefore, zinc iodide can be used as a specific iodine source and zinc source.

When the iodide salt is _{a metal salt other than zinc iodide (ZnI 2} ), it is preferably used together with a zinc salt other than zinc iodide. For example, when the iodide salt is at least one selected from the group consisting of _{CuI 2} , FeI ₂ , NaI and KI, it is preferably used together with _{zinc acetate ((CH 3} COO) _{2 Zn).} Specific examples thereof include _{a combination of CuI 2} and zinc acetate, a combination of FeI ₂ and zinc acetate, a combination of NaI and zinc acetate, a combination of KI and zinc acetate, and a combination of NaI and zinc acetate. A combination of KI and zinc acetate is preferable, and a combination of NaI and zinc acetate is more preferable.

In the present specification, an iodine element or an iodine ion (iodine ion; I ⁻ ) may be simply referred to as “iodine”, and an iodide ion (I ⁻ ) may be referred to as “iodine ion”. Further, in the present specification, the term "zinc salt" may specifically refer to a zinc salt other than _{zinc iodide (ZnI 2).}

The particular sulfur source is at least one selected from the group consisting of dimethyl sulfoxide (DMSO) and methylsulfonylmethane (MSM). Only one of DMSO or MSM may be used, preferably DMSO. The description of DMSO in this specification can also be applied to MSM.

The composition of this embodiment uses a specific iodine source and a specific sulfur source in combination as a pharmacologically active ingredient (medicinal ingredient, activator), and typically iodine (iodine element, iodine ion) and dimethyl. Contains sulfoxide. It is believed that a particular sulfur source is combined with a particular iodine source to enhance the therapeutic effect of the sulfur source.

How a specific iodine source and a specific sulfur source function and work is not clear, but the specific iodine source or a part thereof or the iodine element produced from the iodine source or The possibility that iodine ions and a specific sulfur source act together, the possibility that iodine ions generated from a specific iodine source act (for example, the possibility of exerting an antiviral effect), the specific sulfur source is an iodine ion,
It may act as a stabilizer and / or carrier for iodine element or iodine source, and even if there may be some adverse effects (side effects, etc.) due to iodine ions, iodine element or iodine source, a specific sulfur source may be affected by the adverse effects. There is a possibility of protecting the living body. For example, even if zinc iodide has a sufficient therapeutic effect and at the same time its iodine ion or iodine element has some adverse effects (side effects, etc.), a specific sulfur source such as DMSO protects the living body from the adverse effects. There is a possibility.

For the prevention and treatment of viral infections and septicemia, current treatment plans typically include _{a combination of zinc iodide (ZnI 2} ) or a mixture of zinc and iodide salts (preferably zinc acetate and iodine). Potassium iodide or sodium iodide), or iodine derivatives, specifically povidone iodide (also referred to as providone iodide, povidone-iodine), is used with dimethylsulfoxide (DMSO). _{Therapeutic compositions combine the two} components described above, namely ZnI 2 or zinc salt / iodide salt or iodine or iodine derivative with DMSO to suppress, prevent, and prevent symptoms of all types of viral infections and septicemia. It showed a strong synergistic effect in treatment.

Viral infections to which the composition of this embodiment can be effective include SARS-COV-2 infections or COVID-19 (eg, Cases 8 and 9 below), viral pneumonia (eg, Case 1 below), and A. Influenza such as type influenza (for example, case 7 below), respiratory virus infection for which a virus such as a general cold has not been identified (for example, cases 2, 3 and 6 below), genital herpes (for example, case below). 4) In addition to herpes infection (case 5 described later may be the case), hepatitis B, hepatitis C, HIV infection, RSV infection, human papillomavirus infection (HPV) and the like can be mentioned.

Viral infections and / or septicemia for which the compositions of this embodiment may be effective include dry cough, severe dry cough, sore throat, squeezing (severe squeezing, etc.), chest and nose stuffiness, headache, chest pain (chest). Pain), muscle pain, body pain, shortness of breath, dyspnea, respiratory insufficiency (acute respiratory insufficiency, etc.), respiratory function limitation, acute bronchitis, fatigue (extreme fatigue, etc.), malaise, cold, pneumonia (inflammatory reaction, etc.) Bilateral lower lobe pneumonia, etc.), chest congestion, pleural effusion, abdominal distension, abdominal pain, heart failure, dyspnea with a heart rate of 114 to 115 per minute, dyspnea such as 32 to 36 breaths per minute, 72 to 86%, etc. Oxygen saturation (SpO ₂ ; 72%, 75%, 86%, etc.), fever of about 38-40 ° C (including 38 ° C, 38.7 ° C, 39 ° C, 39.5 ° C, etc.), liver disease, Elevated liver enzymes and blood lactate levels, increased serum creatine, thrombocytopenia, leukocytopenia, congestive heart failure, stage II renal failure, hypotension, type II insulin-dependent diabetes, acute burning pain, With symptoms and conditions such as genital blisters, painful blisters on both sides of the face and in the mouth, blisters, watery secretions, rectal cancer, loss of appetite, bloody diarrhea (bloody diarrhea), olfactory dysfunction, etc. It may be a thing.

Patients with viral infections and / or septicemia for which the composition of this embodiment may be effective include lung cancer, breast cancer, prostate cancer, cancer such as prostate cancer with metastasis to bone, lung, lymph nodes, gastric inflammation, gastric ulcer, etc. Patients with a history of chronic active hepatitis B, Crohn's disease, asthma, COPD (chronic obstructive lung disease), smoking history, etc. may be used.

The composition of this embodiment is also considered to have effects such as antiviral, anti-inflammatory, antifungal, antibacterial, immunomodulatory, anti-fibrosis, antithrombotic, cardiac and respiratory assisting activities, and these activities allow patients and animals. These symptoms of the virus can also be alleviated.

The compositions of this embodiment also include antibiotics such as penem, vancomycin, solmedrol, paracetamol, dexamethasone, tamiflu, acyclovir, corticosteroids, cough suppressants, bronchial dilators, antipyretics, Ringer-lactate. solution), nutritional supplements, Chinese herbs, administration of other drugs such as other antiviral drugs, treatment such as oxygen therapy (patients, etc.), or when these treatments do not improve the symptoms Even (patients, etc.) can alleviate these symptoms of patients and animals.

The daily dose of a particular iodine source and a particular sulfur source per kg of human or animal body weight is the ratio of sulfur atoms contained in the sulfur source to 1 mole of iodine atoms contained in the iodine source. For example, 20 mol% or more and 200 mol% or less are mentioned, and the lower limit value is preferably 25 mol% or more, more preferably 30 mol% or more, and the upper limit value is preferably 180 mol% or less, more preferably. Is less than 30 mol%.

The daily dose of a specific iodine source per kg of human or animal to 1 part by mass of the dose per kg of body weight of a specific iodine source is that the specific iodine source is an iodide salt. At one time, for example, a range of 5 parts by mass or more and 100 parts by mass or less can be mentioned, and the lower limit value is preferably 10 parts by mass or more, more preferably 20 parts by mass or more, and the upper limit value is preferably 90 parts by mass. It is less than or equal to parts by mass, more preferably 80 parts by mass or less.

The daily dose of a specific iodine source per kg of human or animal to 1 part by mass of the dose per kg of body weight of a specific iodine source is when the specific iodine source is povidone iodine. For example, a range of 5 parts by mass or more and 100 parts by mass or less can be mentioned, and the lower limit value is preferably 10 parts by mass or more, more preferably 20 parts by mass or more, and the upper limit value is preferably 90 parts by mass or more. Hereinafter, it is more preferably 80 parts by mass or less.

The daily dose of a particular iodine source per kg of human or animal body weight is as follows.
(1) When the specific iodine source is an iodide salt, for example, the range of 0.5 mg to 10 mg is mentioned, and the lower limit value is preferably 1 mg or more, more preferably 2 mg or more, and the upper limit value is It is preferably 7 mg or less, more preferably 5 mg or less.
(1-1) When the specific iodine source is an iodide salt, the iodide salt is _{a metal salt other than zinc iodide (ZnI 2} ), and the metal salt is used together with a zinc salt other than zinc iodide. The ratio of the iodide salt, which is a metal salt other than zinc iodide, to 1 mol of the zinc salt other than zinc iodide is, for example, 2 to 5 mol, and the zinc salt other than zinc iodide. The iodide salt, which is a metal salt other than zinc iodide, has a range of, for example, 1 to 20 parts by mass with respect to 1 part by mass, and the lower limit is preferably 2 parts by mass or more, more preferably 3 parts by mass. It is more than parts by mass, and the upper limit is preferably 10 parts by mass or less, more preferably 5 parts by mass or less.
(2) When the specific iodine source is povidone iodine, for example, the range is 0.5 mg to 50 mg, the lower limit value is preferably 1 mg or more, more preferably 2 mg or more, and the upper limit value is preferable. Is 40 mg or less, more preferably 30 mg or less.

The daily dose of a particular sulfur source per kg of human or animal body weight may range, for example, from 10 to 1000 g (10 to 1000 ml), with a lower limit of preferably 100 g (100 ml) or more, more preferably. Is 200 g (200 ml) or more, and the upper limit value is preferably 700 g (700 ml) or less, more preferably 500 g (500 ml) or less. These doses are particularly suitable for DMSO. DMSO can be replaced with methylsulfonylmethane (MSM), preferably at a dose of 10 mg to 150 mg (10 to 150 ml) per kg body weight per day.

Current therapeutic composition component doses The current therapeutic composition component doses are preferably, for example:
Zinc iodide: 0.5-10 mg / kg body weight, preferably 1-5 mg / kg body weight
The mixture of zinc salt and iodide can be used in a ratio of 1 part zinc salt to 2 to 20 parts iodide salt, preferably 1 part zinc salt to 3 to 10 parts iodide salt (eg, 1 part zinc acetate and iodide). 5 parts of potassium or 1 part of zinc acetate and 5 parts of sodium iodide).
Molecular iodine (I ₂ ) or derivative: 0.05-10 mg / kg body weight
Dimethyl sulfoxide (DMSO): 10 to 1000 mg (10 to 1000 ml) per kg of body weight, preferably 100 to 500 mg (100 to 500 ml) per kg of body weight.

Dosage forms of the compositions of this embodiment include, for example, oral liquids, softgels, suspensions, aerosols, gels, oral creams, transdermal agents, nasal and oral spray sprays, eye drops or ear drops. Examples thereof include injections such as preparations, rectal suppositories (suppositories), infusions, intramuscular injections, and intravenous injections, powders, powders, granules, tablets, capsules, pills, and liquids.

The composition of this embodiment may contain other components as long as the desired action is not impaired. Other components include, for example, sweeteners, flavors (flavors), excipients, bases, emulsifiers, solvents (eg, water), stabilizers, pH adjusters and the like.

The composition of this embodiment may be a composition in which a specific iodine source, a specific sulfur source, and in some cases a zinc source are further combined at the time of provision of sale or the like, or the composition of the sale or the like may be provided. At the time, at least one selected from the group consisting of a specific iodine source, a specific sulfur source, and an arbitrary zinc source is separated (as a separate agent or composition) and is used in clinical settings such as at the time of administration. It may be mixed.

Examples of the administration method of the composition of this embodiment include oral administration, nasal administration, spray administration, transdermal administration, eye drops, ear drops, via installation, intramuscular injection, intravenous administration, and intraperitoneal administration. Enteral administration of rectal suppositories and the like can be mentioned, and oral administration, nasal administration, spray administration and intravenous administration are preferable. For example, in the case of oral administration, it can be administered once to several times a day (for example, two or three times).

The administration period of the composition of this embodiment is preferably until the symptoms of viral infection and / or sepsis are alleviated or subsided, for example, 1 hour to 24 hours, for example, 1 hour to 12 hours, 1 hour to after the first administration. Symptom relief such as fever relief (body temperature drop) and pain relief may be seen in a short time such as 6 hours, 1 hour to 3 hours, and 1 hour to 2 hours. For further symptom relief, administration of the composition of this embodiment may be continued for 1 day or longer, for example, preferably 2 days or longer, more preferably 3 days or longer.
The upper limit of the number of days of continuous administration is not particularly limited, and examples thereof include January (within 30 to 31 days), for example, within 15 days, within 12 days, within 10 days, within 5 days, and within 3 days. May be.

<An agent consisting of a specific iodine source and constituting the composition of the first aspect>
A second aspect of the present invention comprises an iodide salt and at least one iodine source selected from the group consisting of povidone iodine, and is an agent for constituting the composition of the first aspect.

The agent of the second aspect is an agent containing a specific iodine source used for constructing, preparing or producing the composition of the first aspect. The agent is prepared and manufactured, for example, as an agent or composition separate from or separated from the agent or composition containing a specific sulfur source and an arbitrary zinc source at the time of provision such as sale or offer for sale. It may be supplied or mixed in clinical settings such as when administered to humans or animals, or it may be a specific iodine source or a specific sulfur source at the time of sale, offer of sale, etc. , And may be used to compose, prepare or produce a single composition of the first aspect comprising any zinc source. Within the scope of this purpose, the above-mentioned matters concerning the first aspect also apply to the second aspect.

<An agent consisting of a specific sulfur source and constituting the composition of the first aspect>
A third aspect of the present invention comprises at least one sulfur source selected from the group consisting of dimethyl sulfoxide and methylsulfonylmethane, and is an agent for constructing the composition of the first aspect.

The agent of the third aspect is an agent containing a specific sulfur source used for constructing, preparing or producing the composition of the first aspect. The agent is prepared and manufactured, for example, as an agent or composition separate from or separated from the agent or composition containing a specific iodine source and an arbitrary zinc source at the time of provision such as sale or offer for sale. It may be supplied or mixed in clinical settings such as when administered to humans or animals, or it may be a specific iodine source or a specific sulfur source at the time of sale, offer of sale, etc. , And may be used to compose, prepare or produce a single composition of the first aspect comprising any zinc source. Within the scope of this purpose, the above-mentioned matters concerning the first aspect also apply to the third aspect.

<Prescription example>
Prescription example 1
Compositions for oral administration can be formulated as follows:
5 g (5000 mg) of zinc iodide with a purity of 99.4% to 99.9% (or 5 g of zinc acetate and 25 g of potassium iodide or 1 part of zinc acetate and 3 to 15 parts (eg, 3 or 3 parts) 5 parts or more, 5 parts or more, 10 parts or 10 parts or less, 15 parts or 15 parts or less) of sodium iodide or potassium iodide) is mixed with 1000 ml of a 99.8% dimethyl sulfoxide solution.
(Composition ZnDM-O)

Prescription example 2
Compositions for intravenous administration can be formulated as follows:
5 g (5000 mg) of 99.8% 99.9% pure zinc iodide (or 99.8% 5 g zinc acetate and 99.8% 25 g sodium iodide) with 1000 ml of dimethyl sulfoxide 99.9% pharmaceutical grade solution. Mix.
(Composition ZnDM-IV)

Prescription example 3
Compositions for oral administration can be formulated as follows:
1000-5000 mg povidone iodine, 50 ml water for injection and 50 ml DMSO
(Composition PVI-DM)

Prescription example 4
Compositions for nasal and oral sprayers can be formulated as follows:
Zinc iodide: 2000 mg, DMSO pharmaceutical grade (98.8-99.9%): 150 ml, water 900 ml
(Composition ZnDM-SP)

Prescription example 5
Compositions for aerosols or by spraying can be formulated as follows:
Zinc iodide 1000-2000 mg, DMSO pharmaceutical grade (98.8-99.8%) 200 ml and water for injection 800 ml
(Composition ZnDM-AN)

Prescription example 6
Compositions for oral administration can be formulated as follows:
One part of zinc iodide can be blended with 5 to 50 parts of methylsulfonylmethane (MSM), for example 5 to 10 parts. The mixture is prepared in capsules or tablets with a total weight of 200-1000 mg, eg 300-500 mg. The daily dose is 1-3 capsules, 3 times daily for the treatment of viral infections and sepsis, including SARS-CoV-2 (COVID-19).

Hereinafter, the details of the present invention will be specifically described with reference to Examples, but the present invention is not limited thereto.

<Examples of preparation of compositions in various dosage forms>
Example 1
The composition for oral administration was formulated as follows.
5 g (5000 mg) of zinc acetate and 15 g (15000 mg) of sodium iodide were mixed with 1000 ml of a 99.8% pure dimethyl sulfoxide solution (composition ZnDM-O).

Example 2
The composition for intravenous administration was formulated as follows.
5 g of 99.8% pure zinc acetate and 25 g of 99.8% pure sodium iodide were mixed with 1000 ml of a 99.9% pure pharmaceutical grade dimethyl sulfoxide solution (composition ZnDM-IV).

Example 3
The composition for oral administration was prepared by mixing with the following formulation.
3750 mg of povidone iodine, 50 ml of water for injection and 50 ml of DMSO (composition PVI-DM).
The daily dose was 2 mg of povidone iodine (or 150 mg for adult patients) per kg of patient body weight.

Example 4
Compositions for nasal and oral sprayers were mixed and prepared according to the following formulations.
Zinc iodide: 2000 mg, DMSO pharmaceutical grade (purity 98.8-99.9%): 150 ml, water 900 ml (composition ZnDM-SP)

Example 5
Compositions for aerosols or by spraying were mixed and prepared according to the following formulations.
Zinc iodide 2000 mg, DMSO pharmaceutical grade (purity 98.8-99.8%) 200 ml and water for injection 800 ml (composition ZnDM-AN)
ZnDM-AN was administered in an amount such that the dose of zinc iodide per dose was 10 mg or the dose of zinc iodide per day was 40 mg.

Example 6: The composition for oral administration can be prepared with the following formulation.
One part of zinc iodide can be blended with 5 to 50 parts of methylsulfonylmethane (MSM), for example 5 to 10 parts. The mixture is formulated in capsules or tablets with a total weight of 200-1000 mg, eg 300-500 mg. The daily dose is 1-3 capsules, 3 times daily for the treatment of viral infections and sepsis, including SARS-CoV-2 (COVID-19).

<Clinical cases of treatment of viral infections and / or sepsis>
Case 1
A 65-year-old male patient with a history of lung cancer was hospitalized with dry cough, sneezing, headache, chest pain, muscle pain, and dyspnea. He showed tachycardia with a heart rate of 115 per minute, a respiratory rate of 36 breaths per minute, 86% oxygen saturation with oxygen therapy, and a fever of 38-39 ° C over the last three days. The patient had been taking antibiotics (penem and vancomycin), cough medicine, and antipyretics for the past three days, but his condition and symptoms did not improve.

Chest x-ray showed right-sided pneumonia and pleural effusion on the left and right sides of the lungs. Patients were treated with penem and vancomycin, given daily dexamethasone 20 mg orally, and Tamiflu, despite normal white blood cell counts at admission. After 24 hours, the patient's general condition and symptoms did not improve. His liver enzymes and blood lactate levels were elevated and serum creatine was elevated. The patient also developed thrombocytopenia and leukopenia. The patient was diagnosed with viral pneumonia and a potentially septic condition. His fever was 39.5 ° C. 3 hours after intravenous injection of 1000 mg of paracetamol.

Patients were infused with 20 ml of the composition ZnDM-IV mixed with 500 ml of 0.9% sodium chloride and started treatment at a rate of 50 drops per minute. Five hours after infusion, the patient's fever dropped to 37.6 ° C. without antipyretics. Patients were then advised to discontinue antibiotic treatment, dexamethasone, Tamiflu and continue with 15 ml ZnDM-IV solution mixed with 500 ml sodium chloride every 12 hours for the next 4 days. His symptoms improved significantly 48 hours after treatment, and cough, chest pain, dyspnea, and fatigue were reduced by more than 50%. His fever was completely controlled in 72 hours.

Patients continued treatment with 20 ml of ZnDM-IV mixed with 500 ml of 0.9% sodium chloride every 24 hours for an additional 10 days. During this treatment with ZnDM-IV, his symptoms continued to improve and his general condition also improved.

Chest x-ray 15 days after treatment with ZnDM-IV showed a reduction of more than 80% in pneumonia on the left side and a 60% reduction in pleural effusion on both sides. The white blood cell count and blood lactate level were in the normal range. Patients with thrombocytopenia, liver enzymes, and creatine were all reduced compared to data prior to ZnDM-IV treatment.

Case 2
A 43 year old man. He showed fever of 38.5 ° C, dyspnea, myalgia, dry cough, and severe sneezing. His symptoms started 12 hours ago and were significantly worse. The patient had a history of gastritis, gastric ulcer, and chronic active hepatitis B. The patient has been taking antiviral drugs for the past two years. Due to his liver disease, the patient is unable to take antipyretics for the current symptoms. The patient was diagnosed with a respiratory viral infection and began treatment every 8 hours with 5 ml of ZnDM-O mixed with 150 ml of water. After 6 hours of treatment with ZnDM-O, all symptoms associated with the current illness improved significantly and his fever dropped to 37.6 ° C. without antipyretic therapy. Patients continued to take 5 ml of ZnDM-O 3 times daily for 6 days. His symptoms associated with respiratory viral infections were completely controlled in 72 hours. The patient's health was normalized 5 days after the start of treatment with ZnDM-O.

Case 3
An 82-year-old woman with a history of breast cancer and no specific treatment history presented with congestive heart failure, stage II renal failure, hypotension, and type II insulin-dependent diabetes mellitus. On admission, the patient exhibited a fever of 39 ° C., a severe dry cough, sore throat, muscle pain, chest and nose stuffiness, tachycardia with a heart rate of 114 minutes per minute, and a respiratory rate of 32 breaths per minute. Despite previous treatment with paracetamol with a total dose of 3000 mg, the patient's symptoms did not improve. The patient's blood cell count was normal and the biochemical panel showed a significant increase in C-reactive protein to 146 mg / L, SGPT to 121 IU / L, and SGOT to 114 IU / L. A chest x-ray of the patient showed no signs of pneumonia and no reduction in lung volume.

Patients started treatment with 4 ml ZnDM-O every 6 hours with 100 ml of water. Six hours after treatment, the patient's fever dropped to 37.8 ° C. without antipyretics. Her symptoms were alleviated, and after 24 hours of treatment with ZnDM-O, the patient's fever dropped to 37.4 ° C., with a heart rate of 98 beats per minute and a respiratory rate of 28 breaths per minute.

Patients continued treatment with 4 ml of ZnDM-O mixed with 100 ml of water three times daily for the next 9 days. Her fever completely recovered after 72 hours of treatment, and her symptoms associated with the current viral infection were significantly reduced by the 5th day of treatment. After 10 days of treatment with ZnDM-O, the patient showed no significant signs associated with respiratory viral infection.

Case 4
A 51 year old woman. He complained of acute burning pain due to blisters on the vulva. The patient was diagnosed with genital herpes, and taking acyclovir 400 mg three times daily for the past three days did not significantly improve symptoms, but the size of the vulvar blisters was minimized.
Patients started treatment with 5 ml ZnDM-O mixed with 150 ml of water three times daily.

Six hours after the initial treatment of ZnDM-O, the patient's pain level was reduced by more than 50%. The patient stopped taking acyclovir and continued to take 5 ml of ZnDM-O three times daily, mixed with 150 ml of water, for the next 9 days. Her pain completely subsided in 3 days and the vulvar blisters healed within 6 days after treatment with ZnDM-O.

Case 5
A 76 year old woman. There were painful blisters on both sides of the face and in the mouth, and a fever of 38 ° C. Despite administration of 400 mg of acyclovir three times daily for 3 days, the number of blisters increased and secretions were formed on the face and mouth. Patients started treatment with 5 ml of ZnDM-O mixed with 150 ml of water three times daily. Her pain level decreased significantly 6 hours after the start of treatment and was completely suppressed at 72 hours. Blisters and watery secretions were significantly reduced 24 hours after treatment with ZnDM-O. The blisters healed after 12 days of treatment.

Case 6
A 74-year-old male patient suffered from end-stage rectal cancer. He developed fatigue, chills, cough, chest pain, and high fever for 3 days before admission. The patient was diagnosed with a respiratory viral infection and acute bronchitis. At admission, the patient's temperature rose to 39.8 ° C. After 24 hours of treatment consisting of antibiotic treatment, oxygen therapy, antipyretic therapy, and infusion of Ringer-lactate solution, the patient's fever maintained a temperature of 39.5 ° C and his condition. Exacerbated with symptoms of extreme fatigue, headache, dyspnea, abdominal distension, and heart failure.

Patients started treatment with oral administration of 1 ml PVI-DM composition mixed with 150 ml of water every 6 hours. The patient's condition improved rapidly 2 hours after starting PVI-DM treatment, and his temperature dropped to 38.3 ° C. His symptoms of heart failure and dyspnea gradually improved during the 10 days of treatment.
Patients continued oral treatment with 1 ml PVI-DM mixed with 150 ml of water three times daily without antibiotics for the next 9 days. The symptoms of his pathogenic disease were controlled after 4 days and his general health improved significantly. The patient was discharged 11 days later.

Case 7
A 69-year-old man had a high fever, sore throat, and dry cough that lasted for 5 days. The patient was diagnosed with influenza A infection. The patient had a long history of smoking and COPD. He did not receive any specific treatment, but used dietary supplements and herbal medicines to control his COPD symptoms. Patients received antibiotics, solmedrol injections, oral paracetamol, bronchodilator sprays and Tamiflu. Despite the treatment, his fever and cough remained three days after starting the treatment. On the fourth day, the patient developed a _SpO 2 87% of acute respiratory failure in 6L / min oxygen mask. A chest x-ray detected signs of pathogen-related pneumonia in the sputum. Patients started treatment by spraying 5 ml ZnDM-AN with oxygen every 4 hours. After two treatments with ZnDM-AN, his fever and cough improved significantly and SpO ₂ increased to 94% with an oxygen mask of 3 L / min. After 4 treatments with ZnDM-AN, the patient had no fever and did not need any more antipyretics. The dose of solmedrol was reduced to 50% and the drug was completely eliminated 8 days after treatment.

Patients continued treatment with ZnDM-AN spray 4 times daily and were released from oxygen therapy and corticosteroids 5 days after the start of treatment. A chest x-ray 7 days after treatment showed a marked improvement in pneumonia (inflammatory response) and lung respiratory capacity. Twenty-one days after the start of ZnDM-AN administration, he was discharged from the hospital with no symptoms of pneumonia and good lung function.

<Preparation example of therapeutic composition of COVID-19 (SARS-COV-2)>
Example 7
The composition for oral administration was prepared by mixing with the following formulation.
Zinc iodide 10 grams (10,000 mg) Purity 98.0% -99.8%
Dimethyl sulfoxide pharmaceutical grade 98.8% -99.9% 400ml
600 ml of water
(Composition ZnDM-COVID-O)

Example 8
Compositions for intravenous administration can be formulated as follows:
Zinc iodide 5 grams (5,000 mg) Purity 98.0% -99.8%
Dimethyl sulfoxide pharmaceutical grade 98.8% -99.9% 600ml
400 ml of water
(Composition ZnDM-COVID-IV)

Example 9
Compositions for nasal passages, oral sprays and sprays were prepared by mixing with the following formulations.
Zinc iodide 2,000 mg Purity 98.0% -99.8%
Dimethyl sulfoxide pharmaceutical grade 98.8% -99.9% 200 ml
800 ml of water
(Composition ZnDM-COVID-SN)

<Clinical case of COVID-19 treatment>
Case 8
A 76 year old man. With a history of prostate cancer with metastases to bones, lungs and lymph nodes and a history of moderate smoking for 51 years, a fever of 38.7 ° C, muscle and body aches, a severe dry cough with dyspnea, Appeared in the clinic with sore throat, abdominal pain, and extreme fatigue. The patient's symptoms developed and worsened within 6 days and were COVID-19 positive in the RT-PCR test of the nasopharyngeal swab material. The patient underwent x-ray examination and the results showed bilateral lower lobe pneumonia. The patient's SpO ₂ level was 72% and the pulse rate was 120 per minute. Patients initiated bronchodilator inhalation, parasetamol 1000 mg IV, and oxygen therapy with 10 ml ZnDM-COVID-O mixed with 200 ml water via a mask at 6 liters per minute. Two hours after the first treatment, the patient's condition improved significantly. His muscle and body aches were dramatically reduced, SpO ₂ increased to 92% with 3 liters of oxygen therapy per minute, pulse rate was 98 per minute, and fever decreased to 36.7 ° C. .. Patients were receiving 10 ml of ZnDM-COVID-O with 200 ml of water 6 hours after the first treatment without other therapeutic agents. Ten hours after the start of treatment, the patient's pain, respiratory pattern, and energy all improved, body temperature remained normal, SpO ₂ was 94%, no oxygen therapy was needed, and dry cough was reduced by more than 70%. I slept for 3 hours for the first time in 3 days and was able to eat and drink twice as much as the day before. Patients were treated with 10 ml ZnDM-COVID-O every 8 hours for the next 48 hours. He continued to improve clinically in all of the medical conditions and symptoms he complained of. 72 hours after the start of treatment, the patient's body temperature was normal, he slept for 5 hours at night, improved appetite, energy, shortness of breath by more than 70%, had no dry cough, and was associated with prostate cancer experienced before the diagnosis of COVID-19. I didn't even have the pain in my body and chest. His SpO ₂ was 95% and his pulse rate was 86 per minute.

Patients continued to take 10 ml of ZnDM-COVID-O 3 times daily for an additional 7 days. By the 10th day of treatment, all his symptoms associated with COVID-19 had disappeared and his general health had improved significantly. X-ray examinations performed by day 11 showed that bilateral hypolobe pneumonia had completely disappeared. The patient continued to take 5 ml of ZnDM-COVID-O 3 times a day for another 5 days, after which he was discharged from the clinic on the 16th day. The COVID-19 test by RT-PCR of nasopharyngeal swab material on days 14 and 16 was negative for SARS-CoV-2 RNA.

Case 9
A 54-year-old man with a history of Crohn's disease and asthma has a high fever of 39.5 ° C, severe shortness of breath, dry cough, chest congestion and pain, bloody diarrhea, extreme fatigue, body aches and anosmia. He visited the hospital complaining of anosmia. Chest X-ray confirmed bilateral pneumonia with haze. The patient was diagnosed with suspected COVID-19 by close contact with a close relative who was confirmed to have COVID-19 infection 7 days ago. The patient's SpO ₂ was 75%, oxygen therapy was given at 5 liters per minute through a mask, and the pulse rate was 110 per minute.

Patients administer ZnDM-COVID-O at a dose of 5 ml with 200 ml of water every 6 hours, spray 5 ml of ZnDM-COVID-SN every 8 hours, administer 1000 mg of paracetamol intravenously, and administer a bronchodilator. It was inhaled and treated for 72 hours. Four hours after the first treatment, dry cough, shortness of breath, fatigue, and chest pain were significantly reduced and the patient's symptoms improved. The SpO ₂ reading was 92% with oxygen therapy at 3 liters / minute, and the pulse rate dropped to 92 per minute. His body temperature was 37.2 ° C. 72 hours after the start of treatment with ZnDM-COVID, all symptoms of patients associated with the current disease are improved and they can breathe without significant shortness of breath or chest pain without oxygen therapy and bronchodilator treatment. It became so.
His body temperature was in the normal range, SpO ₂ was 96%, and his pulse rate was 85 per minute.
The patient continued treatment with 5 ml of ZnDM-COVID-O every 6 hours without spraying and oxygen treatment for 12 days. Six days after the start of treatment, there were no symptoms associated with the current illness and respiratory restriction. His bloody diarrhea was completely recovered from the 4th day of treatment. On the 4th day, the diagnosis of COVID-19 was confirmed by RT-PCR examination of the nasopharyngeal swab material collected at the time of admission.
X-ray examination on day 15 showed no signs of pneumonia. The RT-PCR test of nasopharyngeal swab material on days 14 and 16 was negative for SARS-CoV-2 RNA.

Claims (16)

A substance that produces iodine ions by dissolution in water and / or after administration, and at least one iodine source selected from the group consisting of povidone iodine, and at least one sulfur selected from the group consisting of dimethyl sulfoxide and methylsulfonylmethane. Compositions for the prevention or treatment of chronic or acute viral infections and / or septicemia in humans or animals, including sources. Chronic or acute human or animal sources containing at least one iodine source selected from the group consisting of iodide salts and povidone iodine and at least one source of sulfur selected from the group consisting of dimethyl sulfoxide and methylsulfonylmethane. Compositions for the prevention or treatment of viral infections and / or sepsis. The composition according to claim 1 or 2, wherein the sulfur source is combined with the iodine source to enhance the therapeutic effect of the sulfur source. The daily dose of the iodine source and the sulfur source per kg of human or animal body weight is 20 mol or more and 200 mol or less of sulfur atoms contained in the sulfur source per 1 mol of iodine atoms contained in the iodine source. The composition according to any one of claims 1 to 3, which is the ratio of. The daily dose of the iodine source for humans or animals per kg of body weight is 1 part by mass, relative to the dose of the iodine source per day for 1 kg of human or animal body weight.
When the iodine source is an iodide salt, it is 5 parts by mass or more and 100 parts by mass or less.
The composition according to any one of claims 1 to 4, wherein when the iodine source is povidone iodine, the amount is 5 parts by mass or more and 100 parts by mass or less. The daily dose of the iodine source per kg of human or animal body weight is
When the iodine source is an iodide salt, it is 0.5 mg to 10 mg.
When the iodine source is povidone iodine, it is 0.5 mg to 50 mg.
The composition according to any one of claims 1 to 4, wherein the daily dose of the sulfur source per 1 kg of human or animal body weight is 10 to 1000 mg. The daily dose of the iodine source per kg of human or animal body weight is
When the iodine source is an iodide salt, it is 1 mg to 5 mg.
When the iodine source is povidone iodine, it is 1 mg to 40 mg.
The composition according to any one of claims 1 to 5, wherein the daily dose of the sulfur source per 1 kg of human or animal body weight is 100 to 500 mg. The iodine source is an iodide salt, the iodide salt is _{a metal salt other than zinc iodide (ZnI 2} ), and the metal salt is used together with a zinc salt other than zinc iodide.
The composition according to any one of claims 1 to 7, wherein the iodide salt, which is a metal salt other than zinc iodide, is 2 to 20 parts by mass with respect to 1 part by mass of the zinc salt other than zinc iodide. thing. The iodine source is an iodide salt, the iodide salt is _{a metal salt other than zinc iodide (ZnI 2} ), and the metal salt is used together with a zinc salt other than zinc iodide.
The composition according to any one of claims 1 to 7, wherein the iodide salt, which is a metal salt other than zinc iodide, is 3 to 10 parts by mass with respect to 1 part by mass of the zinc salt other than zinc iodide. thing. The iodine source is an iodide salt,
The composition according to any one of claims 1 to 7, wherein the iodide salt is _{at least one selected from the group consisting of ZnI 2} , CuI ₂ , FeI _{2, NaI and KI.} The iodine source is an iodide salt,
The composition according to any one of claims 1 to 7, wherein the iodide salt is _{a metal salt other than zinc iodide (ZnI 2} ) and is used together with a zinc salt other than zinc iodide. The composition according to claim 11, wherein the iodide salt is at least one selected from the group consisting _{of CuI 2} , FeI _{2 , NaI and KI and is used together with zinc acetate ((CH 3} COO) _{2 Zn).} .. Any of claims 1-12, which is at least one pharmaceutically acceptable dosage form selected from the group consisting of oral, parenteral, rectal, nasal spray, oral spray, transdermal, infusion, and aerosol spray. The composition according to item 1. The composition according to any one of claims 1 to 13, for the prevention or treatment of COVID-19. An agent for constituting the composition according to any one of claims 1 to 14, which comprises at least one iodine source selected from the group consisting of an iodide salt and povidone iodine. An agent for constituting the composition according to any one of claims 1 to 14, which comprises at least one sulfur source selected from the group consisting of dimethyl sulfoxide and methylsulfonylmethane.